HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment

Files in This Item:
Sho37-6_569-573.pdf509.71 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/52797

Title: Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment
Authors: Hayakawa, Mineji Browse this author →KAKEN DB
Yamamoto, Hiroshi Browse this author
Honma, Taeko Browse this author
Mukai, Nobutaka Browse this author
Higashiyama, Asumi Browse this author
Sugano, Masahiro Browse this author
Kubota, Nobuhiko Browse this author
Uegaki, Shinji Browse this author
Sawamura, Atsushi Browse this author →KAKEN DB
Gando, Satoshi Browse this author →KAKEN DB
Keywords: Disseminated intravascular coagulation
thrombomodulin
renal dysfunction
prothrombinase activity
protein C
clearance
Issue Date: Jun-2012
Publisher: Lippincott Williams & Wilkins
Journal Title: Shock
Volume: 37
Issue: 6
Start Page: 569
End Page: 573
Publisher DOI: 10.1097/SHK.0b013e318252bc82
PMID: 22552020
Abstract: Recombinant human soluble thrombomodulin (TM-α) was recently developed as an anticoagulant for patients with disseminated intravascular coagulation (DIC). However, the pharmacokinetics and pharmacodynamics of TM-α in DIC patients with severe renal impairment have not yet been elucidated. We investigated the pharmacokinetics and pharmacodynamics of TM-α in DIC patients with severe renal impairment. Eleven DIC patients with the severe renal impairment (creatinine clearance (CLcr) <30 ml/min) and 10 DIC patients without severe renal impairment (CLcr ≥ 30 ml/min) were included in this study. In all patients, a dose of 380 U/kg of TM-α was administered during a 30 min infusion. Blood samples were taken before the start of the first TM-α administration, and at 0.5, 2, 4, 8, and 24 h after the start of administration. Although the clearance of TM-α in the patients with renal impairment was 80% of that in the patients without renal impairment, none of the pharmacokinetic values were significantly different between the groups. In the pharmacokinetic simulation, however, the trough levels of TM-α increased gradually in the patients with renal impairment when the same dose of TM-α was repeatedly administered. After the administration of TM-α, the prothrombinase activities in the patients in both groups were sufficiently inhibited during the observation period. Although the pharmacokinetic values in DIC patients with severe renal impairment were only slightly different from those in DIC patients without severe renal impairment, we need to pay attention to the elevation of the trough levels of TM-α when the same dose of TM-α is repeatedly administered.
Rights: This is a non-final version of an article published in final form in Shock, June 2012, 37(6), p 569-573
Relation: http://journals.lww.com/shockjournal/pages/default.aspx
Type: article (author version)
URI: http://hdl.handle.net/2115/52797
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 早川 峰司

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University